Evidence map›Paper›PMID 37578571›Full record

ArticleEJNMMI radiopharmacy and chemistry2023

In vitro characterisation of [

Ashleigh Hull, William Hsieh, William Tieu, Dylan Bartholomeusz, Yanrui Li, Eva Bezak

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Progress in the application ofAnnals of nuclear medicine · 2026
    Review
  2. Article
  3. The molecular blueprint of targeted radionuclide therapy.Nature reviews. Clinical oncology · 2025
    Review
  4. Development of [EJNMMI radiopharmacy and chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ashleigh HullAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia. ashleigh.hull@unisa.edu.au.ORCID http://orcid.org/0000-0003-3361-997X
William HsiehAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia.
William TieuSchool of Physical Sciences, The University of Adelaide, Adelaide, SA, 5000, Australia.ORCID http://orcid.org/0000-0002-7161-4152
Dylan BartholomeuszDepartment of PET, Nuclear Medicine and Bone Densitometry, Royal Adelaide Hospital, SA Medical Imaging, Adelaide, SA, 5000, Australia.
Yanrui LiAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia.ORCID http://orcid.org/0000-0002-0930-0590
Eva BezakAllied Health and Human Performance Academic Unit, University of South Australia, City East Campus, Cnr North Tce and Frome Road, Adelaide, SA, 5001, Australia.ORCID http://orcid.org/0000-0002-1315-1735
Royal Adelaide Hospital · AUUniversity of South Australia · AUThe University of Adelaide · AU

Funding

Australian Government Research Training Program ScholarshipAustralian Nuclear Science and Technology Organisation 2021 ANSTO/ANZSNM Research GrantPanKind, The Australian Pancreatic Cancer Foundation 2019 Avner Innovation Grant
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) continues to be a malignancy with an unmet clinical demand. Development of radioimmunoconjugates which target cancer-specific receptors provides an opportunity for radioimmunotherapy of both metastatic and primary PDAC. In this study, we characterised the in vitro behaviour of a novel beta-emitting radioimmunoconjugate [

resultsA series of in vitro experiments were performed on PDAC cell lines (PANC-1, CAPAN-1, BxPC-3 and AsPC-1) exhibiting strong to weak MUC1-CE expression. [

conclusion[

Indexed as

C595Lutetium-177MUC1Pancreatic cancerRadioimmunotherapy

Identifiers

PMID37578571
PMCPMC10425306
OpenAlexW4385798886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.